A research team investigates the potential of induced pluripotent stem cells (iPSCs) to treat a patient with type 1 diabetes mellitus. The patient's own skin fibroblasts are reprogrammed into iPSCs using the Yamanaka factors (Oct4, Sox2, Klf4, c-Myc). These iPSCs are then differentiated into pancreatic beta cells.
Data collected after 14 days of differentiation:
- Untreated iPSCs:
15% expressed the beta-cell marker PDX1
- Embryonic stem cells (ESCs) under the same protocol:
72% expressed PDX1
- iPSCs pre-treated for 48 hours with a histone deacetylase inhibitor (HDACi):
68% expressed PDX1
- Genome analysis of iPSCs before and after HDACi treatment: no change in DNA sequence;
40% increase in acetylation of histone H3 at the PDX1 gene promoter